New scientific advisor for Redbiotec

Redbiotec, a Redalpine Capital I portfolio company, has announced the successful reaching of the next milestone in their Cytomegalovirus (CMV) program. The company entered the field of virus-like particle (VLP)-based vaccines in 2008, using its proprietary rePAX® co-expression technology for the efficient generation of multi-component VLPs and other protein assemblies. In a recent in vivo study, promising first results were obtained with Redbiotec’s CMV program. This is a prime example of how Redbiotec’s platform rePAX® makes challenging vaccines tangible. Based on these results Redbiotec is in a strong position towards the evaluation of the best lead by the end of 2013.

In addition to its CMV program, Redbiotecs unique pipeline also covers the areas of Human Papillomavirus (HPV) and Influenza. In this regard, Redbiotec demonstrated that applying its proprietary rePAX® platform, Influenza VLP vaccines can be efficiently produced and manufacturing times are reduced by more than 50%.

Redbiotec is also proud to announce that Prof. Dr. Ralf Wagner, co-founder and CEO of Geneart and renowned virologist, was appointed to Redbiotec’s scientific advisory team. With his strong background in synthetic biology and vaccines he will further strengthen Redbiotec’s position as technology leader in VLP vaccines. His experience as entrepreneur including a public offering (German stock market, 2006) and a successful trade sale (2010) will support Redbiotec in growing its business.